Loading organizations...
Inovio Pharmaceuticals is a clinical-stage biotechnology company focused on developing precisely designed DNA medicines. The company utilizes proprietary technology to engineer DNA plasmids, which function as cellular software, delivered via electroporation. This approach aims to address various health challenges including HPV-related diseases, specific cancers, and infectious diseases.
The company originated as Electrofect, founded in Oslo, Norway, in 1999, before being rebranded as Inovio in October 2001. A key figure in its establishment was Dr. J. Joseph Kim, who co-founded the organization. His vision centered on pioneering novel genetic approaches to disease prevention and treatment, laying the groundwork for the company's current DNA medicine platform.
Inovio’s products are intended for individuals facing or at risk of HPV-related conditions, cancers, and infectious diseases, offering new therapeutic and preventative options. The company’s overarching vision is to advance its DNA medicine platform to transform disease prevention and treatment, ultimately contributing to saving and protecting lives globally.
Key people at Inovio Pharmaceuticals.
Inovio Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines—synthetic DNA plasmids delivered with its proprietary CELLECTRA® electroporation devices—to prevent and treat HPV-related diseases, certain cancers, and infectious diseases, and in 2025 is pushing toward initial commercial approval for its lead candidate INO‑3107 for recurrent respiratory papillomatosis (RRP).[1][6]
High-Level overview
Origin story
Core differentiators
Role in the broader tech/biopharma landscape
Quick take & future outlook
Quick framing: INOVIO is a platform biotech that aims to make DNA‑based medicines practical by coupling optimized plasmids with an owned delivery device; 2024–2025 activities (rolling BLA for INO‑3107 and device/data readouts) are pivotal in determining whether the platform moves from promising clinical science to commercial reality.[6][3]
(If you’d like, I can expand this into a one‑page investor brief, list key clinical data for INO‑3107, or summarize recent financials and guidance.)
Key people at Inovio Pharmaceuticals.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 25, 2022 | Geneos Therapeutics | $17.0M Series A | Ted Fjällman | Global Bio Fund, INOVIO Pharmaceuticals, Korea Investment Partners, Sante Ventures |
| Mar 1, 2021 | Geneos Therapeutics | $12.0M Series A | Korea Investment Partners | INOVIO Pharmaceuticals, Saints Capital |